NovoCure (NVCR) Accumulated Depreciation & Amortization (2014 - 2025)

NovoCure's Accumulated Depreciation & Amortization history runs 12 years deep, the most recent figure standing at $41.9 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation & Amortization rose 29.59% year-over-year to $41.9 million; the TTM figure through Dec 2025 stood at $41.9 million (up 29.59% YoY), while the FY2025 annual figure was $41.9 million, up 29.59% from the prior year.
• Accumulated Depreciation & Amortization came in at $41.9 million for Q4 2025 at NovoCure, up from $32.3 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $41.9 million in Q4 2025 to a low of $22.1 million in Q4 2021.
• A 5-year average of $29.6 million and a median of $28.0 million in 2023 frame the typical range for Accumulated Depreciation & Amortization.
• Across the five-year window, Accumulated Depreciation & Amortization grew 6.82% in 2022 and climbed 29.59% in 2025, its largest moves.
• NovoCure's Accumulated Depreciation & Amortization stood at $22.1 million in 2021, then increased by 6.82% to $23.6 million in 2022, then advanced by 18.47% to $28.0 million in 2023, then increased by 15.56% to $32.3 million in 2024, then increased by 29.59% to $41.9 million in 2025.
• According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $41.9 million, $32.3 million, and $28.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison